Imexpharm Rule of 40
The Rule of 40 of Imexpharm (IMP.VN) as of Oct 5, 2026 is 29.64 %. In the previous year, Rule of 40 was 29.42 % — a change of 0.77% (higher).
Get this data via API
Financial Data API
Rule of 40
29.64 %
YoY
0.77%
Last updated:
Rule of 40 of Imexpharm is 2026 29.64 % . Rule of 40 of Imexpharm was 2025 29.42 % . It decreases by 0.77% higher compared to the previous year.
The Imexpharm Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
15.03 VND
Jan 1, 2019
32.85 VND
Jan 1, 2020
16.82 VND
Jan 1, 2021
12.03 VND
Jan 1, 2022
47.81 VND
Jan 1, 2023
40.42 VND
Jan 1, 2024
29.42 VND
Jan 1, 2025
29.64 VND
| YEAR | Rule of 40 | YoY |
|---|---|---|
| 29.64 % | +0.77% | |
| 29.42 % | -27.23% | |
| 40.42 % | -15.46% | |
| 47.81 % | +297.55% | |
| 12.03 % | -28.49% | |
| 16.82 % | -48.80% | |
| 32.85 % | +118.55% | |
| 15.03 % | -43.13% | |
| 26.43 % | +59.34% | |
| 16.59 % | -10.42% | |
| 18.52 % | — |
Access this data via the Eulerpool API
Imexpharm Stock analysis
What does Imexpharm do? Imexpharm is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Imexpharm stock
Rule of 40 of Imexpharm is 29.64 % in 2026.
On Eulerpool you can find the complete historical development of Rule of 40 Imexpharm since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
Quality — Imexpharm
All Key Metrics — Imexpharm
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth